NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 119 filers reported holding NURIX THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,522,329 | -39.4% | 320,907 | -23.0% | 0.00% | – |
| Q2 2023 | $4,161,964 | -48.0% | 416,613 | -53.7% | 0.00% | – |
| Q1 2023 | $7,996,334 | -27.4% | 900,488 | -10.3% | 0.00% | -100.0% |
| Q4 2022 | $11,020,000 | -49.8% | 1,003,643 | -40.5% | 0.00% | -50.0% |
| Q3 2022 | $21,964,000 | -3.2% | 1,685,651 | -5.9% | 0.00% | 0.0% |
| Q2 2022 | $22,688,000 | +44.3% | 1,790,655 | +59.6% | 0.00% | +100.0% |
| Q1 2022 | $15,720,000 | -51.0% | 1,122,023 | +1.3% | 0.00% | -50.0% |
| Q4 2021 | $32,080,000 | +62.6% | 1,108,103 | +68.2% | 0.00% | 0.0% |
| Q3 2021 | $19,732,000 | +12.9% | 658,617 | 0.0% | 0.00% | +100.0% |
| Q2 2021 | $17,473,000 | -2.9% | 658,617 | +13.7% | 0.00% | -50.0% |
| Q1 2021 | $18,004,000 | +63.1% | 579,085 | +72.5% | 0.00% | +100.0% |
| Q4 2020 | $11,037,000 | -5.8% | 335,685 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $11,719,000 | – | 335,685 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,822,883 | $14,327,860 | 1.60% |
| DAFNA Capital Management LLC | 556,695 | $4,375,623 | 1.36% |
| Redmile Group, LLC | 2,848,827 | $22,391,780 | 1.06% |
| Deep Track Capital, LP | 2,997,830 | $23,562,944 | 0.91% |
| WestHill Financial Advisors, Inc. | 283,333 | $2,226,997 | 0.65% |
| Soleus Capital Management, L.P. | 814,000 | $6,398,040 | 0.59% |
| Affinity Asset Advisors, LLC | 250,000 | $1,965,000 | 0.55% |
| Boxer Capital, LLC | 1,224,892 | $9,627,651 | 0.51% |
| AtonRa Partners | 24,227 | $190,424 | 0.40% |
| WASATCH ADVISORS LP | 3,564,616 | $28,017,882 | 0.18% |